Vivus Inc (VVUS) 5.36 $VVUS
Shares of VVUS Down 41.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 15, 4:45PM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 3 months, Vivus has returned 41.93% as of today's recent price of $5.02.
Biotech Tweet of the Week: Love Being Private
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:57PM CDT
This week's tweet of the week comes from Luke Timmerman, with a quote from Moderna Therapeutics' President and CEO Stephane Bancel, who says he loves being a private company because he has more control over what information gets released. Public...
Avanafil Clinical Data to Be Presented at European Association of Urology
Marketwire - Fri Apr 11, 6:01AM CDT
VIVUS (NASDAQ: VVUS) today announced that a poster describing results of a clinical study examining onset of action of avanafil will be presented during the 29th Annual European Association of Urology (EAU) Congress at Stockholmsmässan in Stockholm, Sweden.
Three VIVUS Directors Not Standing for Re-Election
Marketwire - Tue Apr 08, 4:00PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that J. Martin Carroll, Mark B. Logan and Robert N. Wilson have decided not to stand for re-election when their terms expire at the Annual Meeting of Stockholders, to be held on June 20, 2014.
Vivus Has Returned 39.0% Since SmarTrend Recommendation (VVUS)
Comtex SmarTrend(R) - Mon Apr 07, 9:14AM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 3 months, Vivus has returned 39.04% as of today's recent price of $5.27.
Who Benefits the Most With Obamacare's Enrollment Surpassing 7 Million?
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 06, 11:25AM CDT
For all intents and purposes, with the exception of a select few people who were forced to file an extension due to their inability to meet the March 31 coverage cutoff deadline, enrollment in Obamacare for 2014 is now closed. Source: White...
Why Vivus (VVUS) Stock Is Plunging Today
at The Street - Thu Apr 03, 1:19PM CDT
Shares of Vivus (VVUS) are down 7.12% to $5.74 after Piper Jaffray downgraded the stock earlier today to"underweight" from "neutral."
Food & Beverage Companies Advancing in the Consumer Goods Sector - Company Focuses on Strategic Growth Initiatives for 2014 and Beyond
PR Newswire - Thu Apr 03, 8:05AM CDT
Food and Beverage Companies in the consumer goods sector set sights on growth and improvement both long and short-term: RiceBran Technologies (NASDAQ: RIBT), Whole Foods Market, Inc. (NASDAQ: WFM), The Hain Celestial Group (NASDAQ: HAIN), VIVUS, Inc. (NASDAQ: VVUS), Castle Brands Inc. (NYSE: ROX) and Dean Foods Company (NYSE: DF)
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Apr 03, 8:03AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for The Medicines Company , Omeros Corp. , Opko Health and VIVUS, . FDA accepts The Medicines Company's Biologic License Application for Fibrocaps ...
Downgrade Alert for Vivus (VVUS)
Comtex SmarTrend(R) - Thu Apr 03, 6:57AM CDT
Vivus (NASDAQ:VVUS) was downgraded from Neutral to Underweight at Piper Jaffray today. The stock closed yesterday at $6.18 on volume of 3.1 million shares, below average daily volume of 4.0 million. VIVUS, Inc. develops and manufactures therapies for the treatment of men with erectile dysfunction. The Company is currently marketing MUSE and ACTIS in the United States and has license agreements with other companies to market its products internationally. VIVUS is also conducting clinical trials for another treatment.
VIVUS to Present at Upcoming Investor Conference
Marketwire - Thu Apr 03, 6:01AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that management will present an overview of the company at the following investor conference:
MannKind's Dominating Win Annihilates the Shorts
David Williamson, The Motley Fool - Motley Fool - Wed Apr 02, 6:52PM CDT
The biggest winner in health care, and possibly on the entire market, was MannKind today, up an astonishing 73% after the advisory committee reviewing its inhalable insulin Afrezza to make its recommendation to the FDA for or against, shocked the...
Biotech Auxilium Boosts Position In Men's Health Care
at Investor's Business Daily - Tue Apr 01, 4:31PM CDT
It takes some doing for a small fry to take on Big Pharma. But that's part of the game plan for Adrian Adams, CEO of men's health care-focused specialty biotech Auxilium Pharmaceuticals (AUXL). Adams took Auxilium's helm in December 2011. At the time...
Can Arena and VIVUS Profit From Glaxo's Troubles?
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 6:12PM CDT
Last week, GlaxoSmithKline announced that it was on recalling its over-the-counter obesity drug, Alli, in the U.S. and Puerto Rico because it appears that some packages were tampered with. The drug remains on the shelf in Europe, where there...
Why GlaxoSmithKline PLC Shrugged Off Alli's Recall
George Budwell, The Motley Fool - Motley Fool - Sun Mar 30, 3:30PM CDT
GlaxoSmithKline announced a voluntary recall in the United States and Puerto Rico of its over-the-counter, or OTC, fat-blocking pill Alli last Thursday, after consumers in seven states reported that they had bought bottles containing pills that...
Downtrend Call Working As Vivus Stock Falls 33.8% (VVUS)
Comtex SmarTrend(R) - Fri Mar 28, 4:51PM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 2 months, Vivus has returned 33.83% as of today's recent price of $5.72.
Today’s Top Biotech Stories: Halozyme, Exelixis, and VIVUS
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 25, 8:25AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Halozyme , Exelixis ,...
Newly Published Review Article Summarizes Cardiovascular Benefit-Risk Profile of Qsymia
Marketwire - Tue Mar 25, 6:02AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that a review article has been published online in the Journal of Hypertension, the official publication of the International Society of Hypertension and the European Society of Hypertension, summarizing the cardiovascular benefit-risk profile of Qsymia® (phentermine and topiramate extended-release) capsules CIV. The data suggest that Qsymia can be a safe and effective weight loss option for overweight/obese patients with cardiovascular risk factors such as hypertension or type 2 diabetes.
Pre-Market Pulse - Health Care Sector Stocks -- Research on Exelixis, StemCells, Dendreon, and Vivus
PR Newswire - Mon Mar 24, 9:46AM CDT
On Friday, March 20, 2014, the NASDAQ Composite ended at 4,276.79, down 0.98%, the Dow Jones Industrial Average fell by 0.17% to close at 16,302.77, and the S&P 500 finished at 1,866.52, down 0.29%. Four out of ten sectors ended the session in negative. During the session gains in the Utilities, Materials and Energy sectors positively impacted the broader market, while significant retraction came in from Health Care, Consumer Discretionary and Information Technology sectors. The S&P 500 Heath Care Sector Index finished the day at 675.70, down 1.54%, while the same has gained 5.90% in the last three months. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), StemCells Inc. (NASDAQ: STEM), Dendreon Corp. (NASDAQ: DNDN) and Vivus Inc. (NASDAQ: VVUS). Free technical research on EXEL, STEM, DNDN and VVUS can be downloaded upon signing up at:
Biotech Tweets of the Week: Gilead Sciences and Orexigen
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 7:49PM CDT
Not on twitter? (That should include some of you.) Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.) Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to...
Shares of VVUS Down 41.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 15, 4:45PM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 3 months, Vivus has returned 41.93% as of today's recent price of $5.02.
Biotech Tweet of the Week: Love Being Private
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:57PM CDT
This week's tweet of the week comes from Luke Timmerman, with a quote from Moderna Therapeutics' President and CEO Stephane Bancel, who says he loves being a private company because he has more control over what information gets released. Public...
Avanafil Clinical Data to Be Presented at European Association of Urology
Marketwire - Fri Apr 11, 6:01AM CDT
VIVUS (NASDAQ: VVUS) today announced that a poster describing results of a clinical study examining onset of action of avanafil will be presented during the 29th Annual European Association of Urology (EAU) Congress at Stockholmsmässan in Stockholm, Sweden.
Three VIVUS Directors Not Standing for Re-Election
Marketwire - Tue Apr 08, 4:00PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that J. Martin Carroll, Mark B. Logan and Robert N. Wilson have decided not to stand for re-election when their terms expire at the Annual Meeting of Stockholders, to be held on June 20, 2014.
Vivus Has Returned 39.0% Since SmarTrend Recommendation (VVUS)
Comtex SmarTrend(R) - Mon Apr 07, 9:14AM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 3 months, Vivus has returned 39.04% as of today's recent price of $5.27.
Who Benefits the Most With Obamacare's Enrollment Surpassing 7 Million?
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 06, 11:25AM CDT
For all intents and purposes, with the exception of a select few people who were forced to file an extension due to their inability to meet the March 31 coverage cutoff deadline, enrollment in Obamacare for 2014 is now closed. Source: White...
Why Vivus (VVUS) Stock Is Plunging Today
at The Street - Thu Apr 03, 1:19PM CDT
Shares of Vivus (VVUS) are down 7.12% to $5.74 after Piper Jaffray downgraded the stock earlier today to"underweight" from "neutral."
Food & Beverage Companies Advancing in the Consumer Goods Sector - Company Focuses on Strategic Growth Initiatives for 2014 and Beyond
PR Newswire - Thu Apr 03, 8:05AM CDT
Food and Beverage Companies in the consumer goods sector set sights on growth and improvement both long and short-term: RiceBran Technologies (NASDAQ: RIBT), Whole Foods Market, Inc. (NASDAQ: WFM), The Hain Celestial Group (NASDAQ: HAIN), VIVUS, Inc. (NASDAQ: VVUS), Castle Brands Inc. (NYSE: ROX) and Dean Foods Company (NYSE: DF)
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Apr 03, 8:03AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for The Medicines Company , Omeros Corp. , Opko Health and VIVUS, . FDA accepts The Medicines Company's Biologic License Application for Fibrocaps ...
Downgrade Alert for Vivus (VVUS)
Comtex SmarTrend(R) - Thu Apr 03, 6:57AM CDT
Vivus (NASDAQ:VVUS) was downgraded from Neutral to Underweight at Piper Jaffray today. The stock closed yesterday at $6.18 on volume of 3.1 million shares, below average daily volume of 4.0 million. VIVUS, Inc. develops and manufactures therapies for the treatment of men with erectile dysfunction. The Company is currently marketing MUSE and ACTIS in the United States and has license agreements with other companies to market its products internationally. VIVUS is also conducting clinical trials for another treatment.
VIVUS to Present at Upcoming Investor Conference
Marketwire - Thu Apr 03, 6:01AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that management will present an overview of the company at the following investor conference:
MannKind's Dominating Win Annihilates the Shorts
David Williamson, The Motley Fool - Motley Fool - Wed Apr 02, 6:52PM CDT
The biggest winner in health care, and possibly on the entire market, was MannKind today, up an astonishing 73% after the advisory committee reviewing its inhalable insulin Afrezza to make its recommendation to the FDA for or against, shocked the...
Biotech Auxilium Boosts Position In Men's Health Care
at Investor's Business Daily - Tue Apr 01, 4:31PM CDT
It takes some doing for a small fry to take on Big Pharma. But that's part of the game plan for Adrian Adams, CEO of men's health care-focused specialty biotech Auxilium Pharmaceuticals (AUXL). Adams took Auxilium's helm in December 2011. At the time...
Can Arena and VIVUS Profit From Glaxo's Troubles?
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 6:12PM CDT
Last week, GlaxoSmithKline announced that it was on recalling its over-the-counter obesity drug, Alli, in the U.S. and Puerto Rico because it appears that some packages were tampered with. The drug remains on the shelf in Europe, where there...
Why GlaxoSmithKline PLC Shrugged Off Alli's Recall
George Budwell, The Motley Fool - Motley Fool - Sun Mar 30, 3:30PM CDT
GlaxoSmithKline announced a voluntary recall in the United States and Puerto Rico of its over-the-counter, or OTC, fat-blocking pill Alli last Thursday, after consumers in seven states reported that they had bought bottles containing pills that...
Downtrend Call Working As Vivus Stock Falls 33.8% (VVUS)
Comtex SmarTrend(R) - Fri Mar 28, 4:51PM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 2 months, Vivus has returned 33.83% as of today's recent price of $5.72.
Today’s Top Biotech Stories: Halozyme, Exelixis, and VIVUS
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 25, 8:25AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Halozyme , Exelixis ,...
Newly Published Review Article Summarizes Cardiovascular Benefit-Risk Profile of Qsymia
Marketwire - Tue Mar 25, 6:02AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that a review article has been published online in the Journal of Hypertension, the official publication of the International Society of Hypertension and the European Society of Hypertension, summarizing the cardiovascular benefit-risk profile of Qsymia® (phentermine and topiramate extended-release) capsules CIV. The data suggest that Qsymia can be a safe and effective weight loss option for overweight/obese patients with cardiovascular risk factors such as hypertension or type 2 diabetes.
Pre-Market Pulse - Health Care Sector Stocks -- Research on Exelixis, StemCells, Dendreon, and Vivus
PR Newswire - Mon Mar 24, 9:46AM CDT
On Friday, March 20, 2014, the NASDAQ Composite ended at 4,276.79, down 0.98%, the Dow Jones Industrial Average fell by 0.17% to close at 16,302.77, and the S&P 500 finished at 1,866.52, down 0.29%. Four out of ten sectors ended the session in negative. During the session gains in the Utilities, Materials and Energy sectors positively impacted the broader market, while significant retraction came in from Health Care, Consumer Discretionary and Information Technology sectors. The S&P 500 Heath Care Sector Index finished the day at 675.70, down 1.54%, while the same has gained 5.90% in the last three months. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), StemCells Inc. (NASDAQ: STEM), Dendreon Corp. (NASDAQ: DNDN) and Vivus Inc. (NASDAQ: VVUS). Free technical research on EXEL, STEM, DNDN and VVUS can be downloaded upon signing up at:
Biotech Tweets of the Week: Gilead Sciences and Orexigen
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 7:49PM CDT
Not on twitter? (That should include some of you.) Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.) Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to...
